NSE: LALPATHLAB | BSE: 539524

Strong Performer, Getting Expensive

Download real time

3190.30 -22.80 (-0.71%)

39.10% Gain from 52W Low

61,675 NSE+BSE Volume

NSE 08 Aug, 2025 3:31 PM (IST)

26,726.9

Market Cap

Market Runner Up

0.4

Beta 1Year

Very Low volatility

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd.

25 May 2017

3190.30

-0.71%

Dr Lal Pathlabs Ltd Q4FY17 results comment

Results Update: Dr. Lal Pathlabs Ltd.

HDFC Securities

Revenue grew by 5.99% to Rs. 219.9 Cr in Q4FY17 when compared to the previous quarter

Emkay released a Buy report for Dr. Lal Pathlabs Ltd. with a price target of 3100.0 on 20 Jul, 2025.

Dr. Lal Pathlabs Ltd.

23 May 2017

3190.30

-0.71%

Dr. Lal Pathlabs - The Right Time to Check-In

Buy: Dr. Lal Pathlabs Ltd.

Target

LKP Securities

growth from ~ 12.0 mn in FY16 to ~ 13.3 mn in FY17 as well as a better sales mix, resulting in improvement in realizations per patient from 660 in FY16 to 688 in FY17. While H1FY17 saw the company's revenues expand at a faster pace where it registered a...

Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr

Dr. Lal Pathlabs Ltd.

03 Jan 2017

3190.30

-0.71%

Dr. Lal PathLabs - Healthy Growth Prospects

Buy: Dr. Lal Pathlabs Ltd.

LKP Securities

cardiology tests & services in its quality laboratories which tested over 15.5 mn & 26.3 mn samples and 7.0 mn & 12.0 mn patients in H1 FY17 & FY16 respectively. Indian healthcare industry - a long term structural growth story At just ~ 4.0 % of GDP, India lags in healthcare spends with changes in demographics, increasing incomes, rising penetration of healthcare & medical insurance and opportunities from medical tourism expected to boost demand for the ~ 3.8 tn Indian healthcare delivery industry. This primary demand driver for diagnostic services is expected to grow at ~ 12.0 % CAGR to ~ 6.9 tn by FY20....

Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr

Dr. Lal Pathlabs Ltd.

07 Dec 2016

3190.30

-0.71%

Dr. Lal Path Labs Ltd: Strong growth and margin expansion in... (Dec 07, 2016)

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Karvy

Strong growth and margin expansion in Q2FY17 on YoY basis: The company has grown into a national level lab with a hub-and-spoke model, that handled 15.5 Mn samples in H1FY17. On an average 7.04 Mn patients are depending on DLPL for the trusted accurate results. Post monsoon period,seasonal vector bound fevers like malaria, dengue, chikungunya contributed 2% to the volume growth and 3% to the revenue during the quarter. DLPL posted agood revenue growth of 21.5% YoY to Rs.2622 Mn in Q2FY17.

Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr

Dr. Lal Pathlabs Ltd.

18 Jul 2016

3190.30

-0.71%

Dr. Lal Path Labs Ltd: Strong Position in North India, Expan... (Jul 18, 2016)

Buy: Dr. Lal Pathlabs Ltd.

Karvy

Strong Position in North India, Expanding in South and West Regions: Dr. Lal Path Labs is the second largest diagnostic chain in domestic market with healthy balance sheet and strong cash flows. The company gets 72% of revenue from North India, and is concentrating more on an engagement model between thecompany and the clients. The future acquisitions and partnerships would provide operating synergies and basis for organic growth in these new regions.

Dr. Lal Pathlabs Ltd. is trading above all available SMAs

Dr. Lal Pathlabs Ltd.

08 Jul 2016, 12:00AM

3190.30

-0.71%

Dr. Lal Path Labs Ltd: Strong Position in North India, Expan... (Jul 18, 2016)

Buy: Dr. Lal Pathlabs Ltd.

Karvy

Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.

Dr. Lal Pathlabs Ltd.

07 Dec 2015

3190.30

-0.71%

Dr Lal Pathlabs Limited- Research Report

Dr. Lal Pathlabs Ltd.

Angel Broking

Dr Lal PathLabs is one of the largest companies in the Indian diagnostic industry, having a market share of 12.0% amongst diagnostic chains. Its one of the fastest growing companies in the space with strong profitability. Dominant player in the industry: The company, according to our estimates, is the second largest player with an estimated ~12% market share in the organised diagnostic chains. It has grown at a CAGR of 20.7% over FY2013-15, primarily driven by volumes which grew 16.7% during the period, while the rest was on back of pricing power. Thus, given the companys dominance in its industry and its cash flows (~Rs148cr cash on the books of the company as of FY2015), we believe that the company can easily leverage growth in the diagnostic healthcare services industry in India, which will grow by a CAGR of 16-17% till FY2018. Strong financials: The company has strong business fundamentals, which are reflected in its financials. It has exhibited a strong 20.7% CAGR on the sales front over FY2013-15, predominately led by volumes and partially on the back of pricing power. On the profitability front, the company has maintained healthy and steady margins in the range of 22-25%. The same...

Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.

Dr. Lal Pathlabs Ltd.

07 Dec 2015

3190.30

-0.71%

Dr Lal Pathlabs Limited

Dr. Lal Pathlabs Ltd.

Angel Broking

Dr Lal PathLabs is one of the largest companies in the Indian diagnostic industry, having a market share of 12.0% amongst diagnostic chains. It's one of the fastest growing companies in the space with strong profitability. Dominant player in the industry: The company, according to our estimates, is the second largest player with an estima..

Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr

Dr. Lal Pathlabs Ltd.

04 Dec 2015

3190.30

-0.71%

Dr Lalpath IPO Note

Dr. Lal Pathlabs Ltd.

BOB Capital Markets Ltd.

The company is a provider of diagnostic and related healthcare tests and services in India. Through the company's integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic...

Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr

Is Dr. Lal Pathlabs Ltd. worth buying?

226 Votes:

Buy 76.11%

Sell 14.6%

Hold 9.29%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf